Information Provided By: 
Fly News Breaks for February 12, 2020
BSX
Feb 12, 2020 | 18:34 EDT
Goldman Sachs analyst Amit Hazan initiated coverage of Boston Scientific with a Neutral rating and $46 price target. The analyst contends that the company should post another year of solid top line growth, but he also sees that already reflected in the stock price and risks weighted to the downside based on the trends in CRM, DES, and other categories. Hazan adds that "MedSurg" offers important drivers of growth, but he sees the 2020 ramp as "less certain".
News For BSX From the Last 2 Days
